All treatments
Treatment
CABOMETYX 60 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune checkpoint inhibitors: A phase II study (Immunocabo)
This study looks at a new treatment called cabozantinib for liver cancer (hepatocellular carcinoma) in people who haven't responded to previous treatments. It aims to see how well it stops the cancer from growing and if it's safe to use. Patients will take tablets.
For: Hepatocellular carcinomaItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
This study is testing a medicine called CABOMETYX for advanced thyroid cancer that hasn't responded to radioactive iodine treatment. Researchers are looking at blood samples to understand how the medicine works and if certain signs in the blood can predict who will benefit most.
For: Advance Radioactive-Iodine Refractory Differentiated Thyroid CancerSpain